Canada: Trends In Life Sciences: From Data Protection To Drug Pricing

1  Privacy & Data Protection

Personal information protection and compliance with privacy laws have taken centre stage with life sciences companies as a result of the increasing use of data in connection with a myriad of products and services, including patient support programs, wearable and other connected devices, mobile apps, digitized health care, genetic testing, and personalized medicine, along with the greater use of data mining and targeted advertising.

Although personal information has tremendous value, companies must remember that Canada has a patchwork of federal and provincial privacy laws, and any given activity may be subject to multiple privacy laws. Further, it is not just patients' private health information that is considered personal information, even information about health-care professionals, de-identified information, and personal details publicly posted on social media platforms can be considered personal information, making the collection and use of that information subject to privacy laws.

Companies must balance a commercial desire to collect as much personal information as possible, in case it is useful or valuable in the future, with the privacy obligations and risks associated with having that information. Data security threats abound, not just from criminal hacking, but also from employee error and theft.

Life sciences companies must actively seek ways to protect personal information and other confidential or proprietary data in order to prevent breaches and mitigate their liability. Proactively addressing cybersecurity vulnerabilities may be even more important for connected device manufacturers where exploitation of a vulnerability could have significant consequences for patient safety.

2 Biologics

Biologics are costly to produce and a number of significant blockbusters are nearing the end of their patent term protection. As companies work toward development and promotion of less costly alternatives, biosimilars (previously called subsequent entry biologics or SEBs in Canada) have garnered a great deal of attention in Canada and throughout the world, especially in terms of whether such drugs can be substituted for the reference-based biologic and on issues of interchangeability.

A biosimilar is a biologic drug that enters the market subsequent to a version previously authorized in Canada and with demonstrated similarity to a reference-based biologic drug. A biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference-based biologic drug, and which influences the amount and type of original data required.

Biologic sales continue to increase as there is a greater global focus on improving health-care access and reducing the cost of care, which presents growth opportunities for biosimilars. We can expect greater focus on issues applicable to biosimilars with regard to their regulatory approval, market entry, use and pricing terms. At the same time, biologics generally can be expected to take on a greater market share and drive industry growth.

3 Drug Pricing and Market Access

Canada is seeing greater attention focused on drug prices and pricing strategies by various stakeholders, including preferred listing agreements with private insurers and provincial tendering. Canada's Patented Medicine Prices Review Board (PMPRB) is currently undertaking an extensive review of its policies and guidelines on how to protect consumers from "excessively priced" patented medicines. Some areas being considered as part of PMPRB's consumer protection mandate include screening based on the potential for abuse of statutory monopoly and minimizing the price gap between public payers, private payers and cash customers.

As drug manufacturers strive to improve market access and sales, broaden distribution channels, and convince insurers to cover their drugs and list them as preferred medications, they are facing increased pressure to lower their prices. Due to complicated drug pricing laws, pricing in one province can impact not just the pricing in other provinces but also pricing in international markets. Provincial laws governing pricing and commercial arrangements in the life sciences sector vary widely among the provinces, and companies must ensure their pricing and commercial strategies and arrangements take into account not just the federal and provincial drug pricing laws in Canada, but also anti-trust laws.

Other strategies that pharmaceutical and medical device manufacturers are employing to increase their revenue streams include:

  • Technology licensing and R&D and co-development collaborations to speed development or leverage the value of intellectual capital
  • Outsourcing arrangements
  • Product and business line acquisitions or divestitures to diversify, build on or consolidate core strengths
  • Investments in, or strategic partnerships with, smaller biotech companies to enhance agility and replenish their product pipeline.

While pharmaceutical and medical device companies have actively pursued these types of activities for the last few years, we expect this trend to continue with life sciences companies relying more heavily on third-party partnerships to drive down prices and bring products to market faster and more cost-effectively.

4 Portfolio Swaps

Pharmaceutical and consumer health-care companies have been adapting to current market dynamics and looking at their geographical footprint to increase growth and synergies through portfolio swaps with other market players. Companies are becoming increasingly strategic when acquiring or selling product lines, and look for portfolio swaps to clarify their business, improve efficiency and increase profit.

Each company participating in the swap looks to sell a product line or portfolio that doesn't align with their current and future business plans to another industry player who in turn owns, and is willing to sell, a product line or portfolio that will give them growth or strength in an area in which they wish to expand. These transactions are viewed as a win-win situation for both buyer and seller, allowing each company to rationalize their businesses and achieve a sharpened focus on their high-performing or core therapeutic areas, and greater coverage of geographic markets internationally.

While we have already seen a high volume of M&A activity within the industry in the last few years, we expect the number of these transactions that will involve product or portfolio swaps between industry players will continue as life sciences companies look to be more strategic with their business.

5 Quebec Legislative Changes

Several legislative changes in Quebec are affecting the public health-care system as well as the practices of health-care professionals and their relationships with industry stakeholders. Some of these legislative amendments have resulted in a large-scale reorganization of the health-care system's management.

The legislation now clearly prohibits physicians in private practice who participate in the public health-care system from charging their patients for "accessory fees" for services, supplies, medications and equipment required to provide an insured health service, or to perform diagnostic tests related to such a service.

Other legislative amendments are impacting the commercial practices of pharmaceutical industry stakeholders. For example, the ceiling on professional allowances that generic drug manufacturers may pay to pharmacists has been lifted. The Minister of Health and Social Services may now enter into listingagreements and proceed through a call for tenders to purchase certain medications from accredited manufacturers in order for the medication price to be included on the list of medications (the Quebec formulary). It may also issue calls for tenders for accredited wholesalers.

The minister will also have the power to suspend or terminate insurance coverage by the public insurance plan of a manufacturer's drug under various circumstances, including when a competitor drug is the object of a listing agreement. A drug manufacturer that has been accredited to have its drug included on the list of medications is also prohibited from entering into an exclusive agreement with an accredited wholesaler or intermediary for the supply in pharmacy of a medication included in the list of medications.

It is too early to determine the full impact that these amendments will have on the industry's commercial practices.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Events from this Firm
12 Sep 2017, Seminar, Toronto, Canada

Please join us as we take an in-depth look at the legislation and the impact on the industry.

14 Sep 2017, Seminar, Toronto, Canada

Change, stress and uncertainty are ever]present factors in todayfs legal environment, and specific aspects about the practice of law make it difficult to thrive in the profession long term. Luckily, there are specific research]based strategies that have been shown to help lawyers thrive and lead to more effective ways to manage stress and pressure.

5 Oct 2017, Seminar, Toronto, Canada

Blakes is proud to host our New to In-House Series, designed to bring together junior and mid-level in-house counsel for a candid exchange of insights to highlight and address some of the challenges and opportunities facing in-house lawyers in their roles today.

 
In association with
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.